99% Pharmaceutical Intermediate Pirfenidone for Treatment Pulmonary Fibrosis

• Model NO.: 53179-13-8
• Customized: Non-Customized
• Suitable for: Adult
• Purity: >99%
• Mf: C12h11no
• Einecs: 1806241-263-5
• Loss on Drying: <1.0%
• Unknown Single Impurity: <0.5%
• Usage: Treatment of Pulmonary Fibrosis
• Transport Package: Discreet Package
• Origin: China

• Powder: Yes
• Certification: HSE, ISO 9001
• State: Solid
• CAS: 53179-13-8
• MW: 185.22
• Appearance: White Powder
• Known Single Impurity: <1.0%
• Grade: Pharma Grade
• Trademark: Saichuang
• Specification: Enterprise standard

Pharmaceutical Intermediate Pirfenidone For Treatment Pulmonary Fibrosis



Quick Detail


What is pirfenidone?

Pirfenidone is used to treat a lung disease called idiopathic pulmonary fibrosis (IPF). IPF causes scar tissue to form deep within your lungs. The scar tissue thickens and becomes stiff or thick over time, which can make it harder for your lungs to work. Decreased lung function can make it hard for you to breathe. Other medical problems can occur when your brain, heart, and other organs do not get enough oxygen.

The cause of IPF is often unknown, but this condition is a progressive disease that can be fatal. Pirfenidone is not a cure for IPF, but this medicine may slow the progress of this disease.

Pirfenidone may also be used for purposes not listed in this medication guide.


Pirfenidone Description:

Pirfenidone is an oral antifibrotic therapy that has been evaluated for the treatment of idiopathic pulmonary fibrosis in three phase 3, randomized, controlled trials. One of these trials was conducted in Japan and involved 275 patients. It was followed by two multinational studies, Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes, that were conducted in the United States, Europe, and Australia and involved 779 patients.7,8 In the Japanese trial, pirfenidone reduced the decline in vital capacity at week 52 and improved progression-free survival. In the multinational trials, the primary end point of change from baseline to week 72 in the percentage of the predicted forced vital capacitywas met in study 004 but not in study 006, prompting U.S. regulatory authorities to request an additional trial to support the approval of pirfenidone.

Pirfenidone is an anti-inflammatory drug used to treat idiopathic pulmonary fibrosis.Antifibrotic agent, effective in models of pulmonary and lung fibrosis.Inhibits collagen production and fibroblast proliferation.Regulates cytokine levels following oral administration in vivo.Potent scavenger of free radicals and inhibitor of lipid peroxidation.Pirfenidone inhibits collagen production and fibroblast proliferation.It has shown antifibrotic and anti-inflammatory properties in variety of animal models of pulmonary fibrosis, and in clinical trials.

Pirfenidone Application:

Pirfenidone has proven antifibrotic and anti-inflammatory properties in various in vitro systems and animal models of pulmonary fibrosis, although its precise mechanism of action remains unclear. It attenuates fibroblast
proliferation, production of fibrosis-associated proteins and cytokines, and the increased biosynthesis and accumulation of extracellular matrix in response to cytokines such as transforming growth F-β. It is also shown to slow tumor cell proliferation by inhibiting fibroblast growth fac, epidermal growth  and platelet-derived growth.

Idiopathic pulmonary fibrosis is characterized by radiographically evident interstitial infiltrates predominantly affecting the lung bases and by progressive dyspnea and worsening of pulmonary function. No therapy has been clearly shown to prolong survival. The current strict definition of idiopathic pulmonary fibrosis provides a new focus for basic and clinical research that will improve insight into the pathogenesis of this disorder and stimulate the development of novel therapies.

In vitro, pirfenidone can inhibit the uterine flesh tumour cells and leiomyoma cells proliferation. Pirfenidone can inhibit the TGF - beta - 1 inducing fibroblast collagen formation. Inhibition of PDGF, FGF and TGF - beta - 1 inducing fibroblast proliferation. In hamster model, pirfenidone, taken by mouth, that can the prevention and treatment of pulmonary fibrosis. Pirfenidone can prevent the sclerosing peritonitis in rats induced by chemical, can also be keloid grafting for the treatment of nude mice. Pirfenidone 0.01 1 mg/ml can suppress the matrix and dose dependent manner serum stimulate uterine fibroids and leiomyoma cell DNA synthesis, the compound has no cytotoxic effect, has no effect on collagen mRNA level also. Pirfenidone in hamster pulmonary fibrosis model can reduce the disease before the collagen I mRNA level enhancement, reduce the level of the lung hydroxyproline and malondialadehyde and lung preserved ammonia acyl hydroxylase activity.


Pirfenidone Adverse effects:

1. Gastrointestinal
Pirfenidone is frequently associated with gastrointestinal side effects such as dyspepsia, nausea, gastritis, gastroesophageal reflux disease (GERD) and vomiting.To reduce the severity of these reactions, pirfenidone is to be taken after meals.
 
2. Skin
Pirfenidone is known to cause photosensitivity reactions, rash, pruritus and dry skin. Patients are usually advised to avoid direct exposure to sunlight, including sun lamps, and to use protective clothing and sunscreening agents. Continuing photosensitivity reactions are usually managed by dose adjustment and temporary discontinuation of treatment if required, along with local symptomatic treatment.
 
3. Hepatic dysfunction
Pirfenidone can increase hepatic enzyme levels, especially those of aspartate transaminase (AST), alanine transaminase (ALT) and gamma-glutamyl transpeptidase (GGT); periodic monitoring of hepatic enzyme levels is required during therapy: once before the initiation of therapy, monthly monitoring until 6 months after initiation of therapy, and 3 monthly thereafter. Extra precaution is required while prescribing the drug in patients with hepatic impairment and in patients who are concomitantly taking a CYP1A2 inhibitor. The drug is contraindicated in patients who have severe hepatic impairment.
 
4. Dizziness and fatigue
Dizziness and fatigue have been reported in patients undergoing pirfenidone treatment. Dizziness typically resolves, although patients should know how they react to pirfenidone before undertaking activities that need mental alertness or coordination. If severe, dose adjustment or treatment discontinuation may be required.
 

5. Weight loss
Weight loss has been reported in patients treated with pirfenidone. Doctors should monitor patients' weight and encourage increased calorific intake if necessary.


Function:

1. Idiopathic pulmonary fibrosis degeneration
2. Liver Fibrosis
3. Renal fibrosis disease
4. Multiple Sclerosis
5. Myocardial fibrosis
6. Neoplastic diseases: neurofibroma, leiomyoma, and malignant gliomas.
7. Prevention of fibrosis after the organ transplant.
8. Rheumatoid arthritis.

Advantage:

1. Quality assurance
With our years of experience, advanced technology and continuous research, our quality is to fully meet the needs of the market to meet the requirements of customers, many customers use our products, we believe that the product is very good. Whether it is a powder, or liquid, yes, we all know, our liquid better.

2. Safe transportation
Our mode of transport is taken according to each country's situation is different transportation, while our packaging, according to the latest customs situation, constantly updated, improved our packaging, we guarantee that you receive it within 3-5 to your product.

3. The product diversity
Our products are powders and liquids, yes, brothers, the effect of the liquid is very good, but many people do not use liquid, so you are very lucky, you buy our powder, we can tell you the method of making the liquid If you buy a liquid, we will tell you how to filter. We absolutely guarantee that you can very safely use our products

4. High quality service 
Our goods packing will not contain any hormone information and can be sent out from different areas of china. At present,the goods customs clearance rate we send to United states and Europe is 99%, As for Canada, Brazil of quite high buckle close rate area, we also have a new way to get through the customs. We also have completely re-send policy to some areas.

 

Cosmetic Raw Materials

Cosmetic Raw Materials,Iodocarb 95%-98%,Iodocarb CAS NO 55406-53-6

Shandong Chenyi Environmental Protection Technology Co.,Ltd , http://www.chenyichem.com